Literature DB >> 2837935

Virus-drug resistance: thymidine kinase-deficient (TK-) mutants of herpes simplex virus. Therapeutic approaches.

E de Clercq.   

Abstract

Mesh:

Substances:

Year:  1987        PMID: 2837935

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


× No keyword cloud information.
  6 in total

1.  Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.

Authors:  E De Clercq; A Holý; I Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.

Authors:  E De Clercq; A Holý
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Antiviral drug sensitivity in ocular herpes simplex virus infection.

Authors:  M J Menage; E de Clercq; A van Lierde; V S Easty; J M Darville; S D Cook; D L Easty
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

4.  In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine.

Authors:  J Neyts; G Jähne; G Andrei; R Snoeck; I Winkler; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

5.  Comparative activity of various compounds against clinical strains of herpes simplex virus.

Authors:  G Andrei; R Snoeck; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

Review 6.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.